Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's ...

Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t ...

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic ...

Good news from the laboratory put some zip into AstraZeneca (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.